Tests GIM-531 alone and with anti-PD-1 in advanced solid tumors
Tests GIM-531, a pill, alone or with anti-PD-1 in adults with advanced cancer.
Key facts
- Who runs it
- Georgiamune Inc
- Where
- Bakersfield, Billings, Boston, Cincinnati, Fullerton, Los Angeles, Nashville, New York, Richmond, San Francisco, and Scottsdale, United StatesSee the 11 sites
- Trial code
- Registry title
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 117 people, planned
- Started
- 9 May 2024
- Expected to end
- Nov 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- GIM-531
- Anti-PD-1 monoclonal antibody
- Record updated
- 14 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or spreading solid tumors that got worse on standard treatment. It tests GIM-531 alone or with an anti-PD-1 drug.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Locally advanced or metastatic solid tumor that got worse on standard therapy, has no standard therapy, or where standard therapy was not tolerated. Disease must be measurable (RECIST v1.1). Some parts of the trial ask for specific cancers: lung cancer (NSCLC), triple-negative breast cancer (TNBC), platinum-resistant ovarian cancer, or tumors with AKT3 mutation/amplification. The phase 2 part asks for unresectable Stage III or metastatic Stage IV cutaneous melanoma, NSCLC, or RCC that got worse on anti-PD-1 therapy.
- Earlier treatment
- No experimental drug within 4 weeks or 5 half-lives (whichever is shorter) before the study drug. No chemotherapy or immune-modulating cancer drugs in that same window. Expansion cohorts allow no more than 3 prior lines of therapy (ovarian cancer: no more than 1 after platinum resistance). Phase 2 asks for anti-PD-1 therapy as the latest treatment, with no more than 2 or 3 prior lines depending on cancer type and BRAF status.
- Biomarker or test result
- Tumors with AKT3 mutation or amplification (found by next generation sequencing) for one cohort. Phase 2 sorts people by BRAF status: BRAF wild-type or BRAF (V600) mutant melanoma, NSCLC or RCC.
Main reasons for not taking part
- Ongoing toxicity above Grade 1 from earlier therapy
- Brain metastases, spinal cord compression or leptomeningeal disease (treated, stable brain metastases allowed)
- Heart disease, serious heart rhythm problems or long QT syndrome
- Active autoimmune disease needing systemic treatment in the past 12 months, or immunosuppressive therapy
- Active infection including hepatitis B, hepatitis C or HIV, or an immunodeficiency
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Written informed consent
- Cytologically or histologically confirmed locally advanced or metastatic solid tumor that has progressed on standard therapy or for which no standard therapy exist; or be intolerant of standard therapy
- Have not received an experimental drug within 4 weeks or 5 half-lives (whichever is shorter) of study drug treatment or already be enrolled in a clinical study
- ECOG performance status 0-1
- Laboratory and ECG assessments within 28 days of enrollment including acceptable cardiac, renal, and hepatic functions
- Agree to baseline core needle biopsy or archival (within 12 months of screening) tumor submission; Note: Participants whose only site(s) of disease are in areas considered moderate or high risk for biopsy complications may be enrolled without a fresh biopsy upon Sponsor approval
- Non pregnant participants; female participants of child bearing potential with non-sterile partners agree to use an effective form of contraception from the time of first dose of study drug (or 14 days prior to first dose for oral contraception) until 7 months after the last dose of study drug. Effective forms of contraception include hormonal (injection or oral), double barrier method, or intrauterine device. Non-sterile male participants with sexual partners of childbearing potential agree to use a barrier contraception method and agree to not donate sperm from the time of first dose of study drug until 4 months after the last dose of study drug
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1; Phase 1 Expansion Cohorts Specific Inclusion Criteria (in addition to above inclusion criteria):
- NSCLC: Participants must have locally advanced/unresectable or metastatic NSCLC. Participants must have received no more than 3 prior lines of therapy in the advanced/metastatic setting
- TNBC: Participants must have locally advanced unresectable, recurrent, or metastatic TNBC. Participants must have received no more than 3 prior lines of therapy in the advanced/metastatic setting
- Ovarian Cancer: Participants must have locally advanced unresectable, recurrent, or metastatic ovarian cancer. Participants must have platinum-resistant ovarian cancer defined as disease recurrence or within 6 months after the last administration of platinum-based chemotherapy. Participants must have received no more than 1 line of therapy after development of platinum resistance. Maintenance treatment with Poly(ADP-ribose) polymerase inhibitors (PARPi) or bevacizumab are not counted as separate lines of therapy
- Tumors with AKT3 mutation/amplification: Participants must have a locally advanced unresectable, recurrent, or metastatic solid malignancy. Participants with known AKT3 mutation/amplification based on next generation sequencing (NGS) performed per local standard of care; Phase 2 Specific Inclusion Criteria (in addition to above inclusion criteria):
- Have confirmed unresectable Stage III or metastatic Stage IV cutaneous melanoma, NSCLC, or RCC that has radiographically progressed (as confirmed by imaging assessed by the Investigator) on an approved single-agent or combination anti-PD-1 therapy
- Must have received the anti-PD-1 therapy containing regimen as the latest line of treatment and be eligible to restart or to continue anti-PD-1 therapy in combination with GIM-531
- BRAF wild-type melanoma or RCC: Participants must have received no more than 2 prior lines of therapy in the advanced/metastatic setting
- BRAF (V600) mutant melanoma or NSCLC: Participants must have received no more than 3 prior lines of therapy in the advanced/metastatic setting
Who cannot take part
- Ongoing >Grade 1 toxicity from prior therapy according to Common Terminology Criteria for Adverse Events v5.0 (Note: Grade 2 alopecia and Grade 2 sensory neuropathy are not exclusionary)
- Has known leptomeningeal disease, spinal cord compression, or brain metastases, except participants with the following:; Brain metastases that have been treated and are clinically stable for at least 4 weeks prior to the first administration of study drug; Note: Participants receiving steroids for brain metastases must be either off steroids or on a stable, or decreasing dose, of <10 mg daily of prednisone (or equivalent) in order to be eligible for enrollment; and; No ongoing neurological symptoms related to the anatomic location of the brain metastases; Note: Neurological symptoms that are considered sequelae to treatment for brain metastases are allowed
- At time of screening, is receiving systemic steroid therapy (greater than or equal to 10 mg/day of prednisone or equivalent) or is taking any immunosuppressive therapy; Note: Use of topical, inhaled, nasal, or ophthalmic steroids is allowed
- Has had prior anti-cancer treatment with chemotherapeutic agents or immune modulating agents within <4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of study drug
- Has received a live vaccine within 30 days of first dose of study drug
- Has had or has planned major surgery within 2 weeks of the first dose of study drug
- Inability to swallow an oral dose of a medication (eg, oral capsules)
- Is taking medications that are considered strong inducers or inhibitors of CYP2C8 or CYP3A4/5, P-glycoprotein (P-gp), breast cancer resistant protein (BCRP), or sensitive substrates of P-gp and BCRP (Appendix C) that cannot be discontinued at least 1 week prior to first dose of study drug and for the duration of the study
- Has known structural cardiac disease
- Has an active autoimmune disease that has required systemic treatment in the past 12 months (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- Has active and clinically significant bacterial, fungal, or viral infection, including known hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- Has a history of, or currently has, an acquired or primary (congenital) immunodeficiency
- Has known serious arrythmia, serious dysrhythmia, history of long QT syndrome, or clinically relevant cardiac conduction abnormalities
- Is taking drugs that modify gastric pH, such as proton-pump inhibitors (PPIs) or H2 blockers. Antacids such as calcium carbonate or aluminum hydroxide-based products are permitted
Where in United States
- Comprehensive Blood and Cancer CenterBakersfield, United StatesContact: Nicole WardTaking people
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of MontanaBillings, United StatesContact: Matt AdlerTaking people
- Massachusetts General HospitalBoston, United StatesContact: Ryan Sullivan, MDTaking people
- University of Cincinnati Cancer CenterCincinnati, United StatesContact: Trisha Wise-Draper, MD (principal investigator)Taking people
- Providence Medical FoundationFullerton, United StatesContact: Kendall KarpTaking people
- The Angeles Clinic and Research Institute- A Cedars-Sinai AffiliateLos Angeles, United StatesContact: Navid Hafez, MDTaking people
- Tennessee Oncology, PLLCNashville, United StatesContact: Jeffery Russell, MD (principal investigator)Taking people
- Weill Cornell Medicine-New York Presbyterian HospitalNew York, United StatesContact: Anna Pavlick, DO (principal investigator)Taking people
- Virginia Commonwealth UniversityRichmond, United StatesContact: Faith McFaddenTaking people
- UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, United StatesContact: Sonia Contreras MartinezTaking people
- HonorHealth Research InstituteScottsdale, United StatesContact: Andrew IslasTaking people
About the trial
What the trial wants to find out
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
The 2 groups in the trial
- Phase 1 Single AgentTreatment being tested
GIM-531 administered orally daily
Treatment: GIM-531
- Phase 2 Combination TreatmentTreatment being tested
GIM-531 administered orally daily in combination with anti-PD-1 therapy
Treatment: GIM-531 and Anti-PD-1 monoclonal antibody
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors
- Plain-language title
- Tests GIM-531 alone and with anti-PD-1 in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 August 2026